Bendamustine: all 237 studies that test it

Page 1 of 3. Open to participants first (24), then studies with results posted, then the rest; newest registration first within each.

• Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNot yet recruitingNCT07725406Phase 1
• Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingNCT07593482Phase 2
• Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin LymphomaRecruitingNCT07225985Phase 1/2
• Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Phase 2
• Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingNCT07169565Phase 1
• Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
• Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingNCT06961500Phase 2
• Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
• BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingNCT06854003Phase 2
• BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingNCT06761911Phase 4
• Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruitingNCT06757894Phase 2
• Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingNCT06561347Phase 2
• MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingNCT06557330Phase 2
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
• BeFluBu vs FluBuRux Conditioning in Haploidentical HCTRecruitingNCT06477549Phase 2
• T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingNCT06043713Phase 1
• A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
• Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingNCT05139017Phase 2/3
• Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease StatusRecruitingNCT04934930Phase 2
• Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
• Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingNCT04587687Phase 2
• Study of Pembrolizumab With Bendamustine in Hodgkin LymphomaRecruitingNCT04510636Phase 2
• CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin LymphomaTerminatedNCT04217317Phase 2Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT03872180Phase 2Results posted
• Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeCompletedNCT03834688Phase 2Results posted
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03739619Phase 1/2Results posted
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 1Results posted
• Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
• Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaCompletedNCT03609593Phase 2Results posted
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
• Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell LymphomaTerminatedNCT03311126Phase 2Results posted
• Bendamustine and Melphalan in MyelomaCompletedNCT03187223Phase 2Results posted
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1Results posted
• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedNCT02927769Phase 2Results posted
• Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone LymphomaCompletedNCT02853370Phase 2Results posted
• A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
• Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02477215Phase 1/2Results posted
• Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell LymphomaTerminatedNCT02420210Phase 2Results posted
• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2Results posted
• A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT02320487Phase 2Results posted
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02224729Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)CompletedNCT02187861Phase 2Results posted
• A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT02071225Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic LeukemiaCompletedNCT02042911Phase 2Results posted
• Carfilzomib With Bendamustine and Dexamethasone in Multiple MyelomaTerminatedNCT02002598Phase 1/2Results posted
• Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
• Study of SyB L-0501 to Treat Relapsed/Refractory Multiple MyelomaCompletedNCT01849848Phase 2Results posted
• Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLCompletedNCT01754857Phase 2Results posted
• Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaActive, not recruitingNCT01754402Phase 1/2Results posted
• Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaActive, not recruitingNCT01661881Phase 2Results posted
• Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)CompletedNCT01657331Phase 1/2Results posted
• Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyCompletedNCT01626352Phase 2Results posted
• A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab TreatmentCompletedNCT01596621Phase 3Results posted
• Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01535924Phase 1/2Results posted
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01520922Phase 2Results posted
• Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01500083Phase 3Results posted
• IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT01491841Phase 1Results posted
• Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT01484626Phase 1/2Results posted
• Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and EtoposideCompletedNCT01458366Phase 1/2Results posted
• S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT01412879Phase 2Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaCompletedNCT01317901Phase 1Results posted
• Bortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaTerminatedNCT01315873Phase 2Results posted
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT01294579Phase 2Results posted
• GIMEMA CLL0809 Study (BendOfa)CompletedNCT01244451Phase 2Results posted
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaCompletedNCT01234766Phase 2Results posted
• Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT01234467Phase 2Results posted
• Bendamustine and Dexamethasone in Patients With Relapsed AL AmyloidosisCompletedNCT01222260Phase 2Results posted
• Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic LeukemiaCompletedNCT01188681Phase 1/2Results posted
• Efficacy and Safety Study of SyB L-0501 for Patients With Multiple MyelomaTerminatedNCT01179490Phase 2Results posted
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple MyelomaTerminatedNCT01177683Phase 1/2Results posted
• Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaCompletedNCT01165112Phase 1/2Results posted
• Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDSCompletedNCT01141725Phase 1/2Results posted
• R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialCompletedNCT01133158Phase 2Results posted
• Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01118845Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01108341Phase 2Results posted
• Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
• Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01088984Phase 1/2Results posted
• Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3Results posted
• Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell LeukemiaActive, not recruitingNCT01059786Phase 2Results posted
• A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)CompletedNCT01056510Phase 4Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01049945Phase 1/2Results posted
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
• Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01010568Phase 2Results posted
• Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung CancerCompletedNCT00984542Phase 2Results posted
• Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLCompletedNCT00974233Phase 2Results posted
• Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00920855Phase 1/2Results posted
• Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple MyelomaCompletedNCT00916058Phase 1/2Results posted
• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2Results posted

← Bendamustine overview